vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and ONESPAWORLD HOLDINGS Ltd (OSW). Click either name above to swap in a different company.
ONESPAWORLD HOLDINGS Ltd is the larger business by last-quarter revenue ($242.1M vs $168.4M, roughly 1.4× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 11.5%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 7.1%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
ESPR vs OSW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $242.1M |
| Net Profit | — | $12.1M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 6.8% |
| Net Margin | — | 5.0% |
| Revenue YoY | 143.7% | 11.5% |
| Net Profit YoY | — | -16.2% |
| EPS (diluted) | $0.32 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $242.1M | ||
| Q3 25 | $87.3M | $258.5M | ||
| Q2 25 | $82.4M | $240.7M | ||
| Q1 25 | $65.0M | $219.6M | ||
| Q4 24 | $69.1M | $217.2M | ||
| Q3 24 | $51.6M | $241.7M | ||
| Q2 24 | $73.8M | $224.9M | ||
| Q1 24 | $137.7M | $211.2M |
| Q4 25 | — | $12.1M | ||
| Q3 25 | $-31.3M | $24.3M | ||
| Q2 25 | $-12.7M | $19.9M | ||
| Q1 25 | $-40.5M | $15.3M | ||
| Q4 24 | — | $14.4M | ||
| Q3 24 | $-29.5M | $21.6M | ||
| Q2 24 | $-61.9M | $15.8M | ||
| Q1 24 | $61.0M | $21.2M |
| Q4 25 | 50.6% | 6.8% | ||
| Q3 25 | -11.4% | 10.2% | ||
| Q2 25 | 8.6% | 9.2% | ||
| Q1 25 | -34.0% | 7.7% | ||
| Q4 24 | -6.4% | 7.9% | ||
| Q3 24 | -31.0% | 10.3% | ||
| Q2 24 | 3.5% | 8.4% | ||
| Q1 24 | 52.5% | 8.0% |
| Q4 25 | — | 5.0% | ||
| Q3 25 | -35.9% | 9.4% | ||
| Q2 25 | -15.4% | 8.3% | ||
| Q1 25 | -62.2% | 7.0% | ||
| Q4 24 | — | 6.6% | ||
| Q3 24 | -57.2% | 8.9% | ||
| Q2 24 | -83.9% | 7.0% | ||
| Q1 24 | 44.3% | 10.0% |
| Q4 25 | $0.32 | $0.12 | ||
| Q3 25 | $-0.16 | $0.23 | ||
| Q2 25 | $-0.06 | $0.19 | ||
| Q1 25 | $-0.21 | $0.15 | ||
| Q4 24 | $-0.14 | $0.13 | ||
| Q3 24 | $-0.15 | $0.20 | ||
| Q2 24 | $-0.33 | $0.15 | ||
| Q1 24 | $0.34 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $16.3M |
| Total DebtLower is stronger | — | $84.0M |
| Stockholders' EquityBook value | $-302.0M | $542.6M |
| Total Assets | $465.9M | $707.1M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $16.3M | ||
| Q3 25 | $92.4M | $29.6M | ||
| Q2 25 | $86.1M | $35.0M | ||
| Q1 25 | $114.6M | $22.6M | ||
| Q4 24 | $144.8M | $57.4M | ||
| Q3 24 | $144.7M | $48.8M | ||
| Q2 24 | $189.3M | $62.5M | ||
| Q1 24 | $226.6M | $65.4M |
| Q4 25 | — | $84.0M | ||
| Q3 25 | — | $85.2M | ||
| Q2 25 | — | $96.2M | ||
| Q1 25 | — | $97.4M | ||
| Q4 24 | — | $98.6M | ||
| Q3 24 | — | $98.7M | ||
| Q2 24 | — | $123.8M | ||
| Q1 24 | — | $138.6M |
| Q4 25 | $-302.0M | $542.6M | ||
| Q3 25 | $-451.4M | $552.8M | ||
| Q2 25 | $-433.5M | $548.3M | ||
| Q1 25 | $-426.2M | $530.6M | ||
| Q4 24 | $-388.7M | $554.5M | ||
| Q3 24 | $-370.2M | $540.1M | ||
| Q2 24 | $-344.2M | $532.7M | ||
| Q1 24 | $-294.3M | $515.5M |
| Q4 25 | $465.9M | $707.1M | ||
| Q3 25 | $364.0M | $732.6M | ||
| Q2 25 | $347.1M | $731.8M | ||
| Q1 25 | $324.0M | $708.7M | ||
| Q4 24 | $343.8M | $746.4M | ||
| Q3 24 | $314.1M | $734.0M | ||
| Q2 24 | $352.3M | $756.8M | ||
| Q1 24 | $373.1M | $763.6M |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $20.0M |
| Free Cash FlowOCF − Capex | — | $14.9M |
| FCF MarginFCF / Revenue | — | 6.2% |
| Capex IntensityCapex / Revenue | 0.0% | 2.1% |
| Cash ConversionOCF / Net Profit | — | 1.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $68.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $20.0M | ||
| Q3 25 | $-4.3M | $33.2M | ||
| Q2 25 | $-31.4M | $20.3M | ||
| Q1 25 | $-22.6M | $10.1M | ||
| Q4 24 | $-35.0M | $16.6M | ||
| Q3 24 | $-35.3M | $28.6M | ||
| Q2 24 | $-7.2M | $18.7M | ||
| Q1 24 | $53.8M | $15.0M |
| Q4 25 | — | $14.9M | ||
| Q3 25 | — | $27.6M | ||
| Q2 25 | — | $17.6M | ||
| Q1 25 | — | $8.4M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | $-35.5M | $27.5M | ||
| Q2 24 | $-7.3M | $17.6M | ||
| Q1 24 | $53.8M | $13.7M |
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 10.7% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | 3.8% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | -68.7% | 11.4% | ||
| Q2 24 | -9.9% | 7.8% | ||
| Q1 24 | 39.0% | 6.5% |
| Q4 25 | 0.0% | 2.1% | ||
| Q3 25 | 0.0% | 2.2% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | 1.5% | ||
| Q3 24 | 0.3% | 0.5% | ||
| Q2 24 | 0.1% | 0.5% | ||
| Q1 24 | 0.1% | 0.6% |
| Q4 25 | — | 1.65× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.02× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 1.15× | ||
| Q3 24 | — | 1.33× | ||
| Q2 24 | — | 1.19× | ||
| Q1 24 | 0.88× | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
